Status:
COMPLETED
Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis
Lead Sponsor:
Abbott
Conditions:
Acute Bacterial Sinusitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To compare the safety and efficacy of a ten-day course of therapy of cefdinir, 600 mg QD, to a ten-day course of therapy of levofloxacin, 500 mg QD, in the treatment of acute bacterial sinusitis.
Eligibility Criteria
Inclusion
- A female must be non-lactating, non-breastfeeding and at no risk for pregnancy.
- A condition of general good health, based upon the results of a medical history, physical examination, and laboratory profile.
- Subject must have a diagnosis of acute bacterial sinusitis. The diagnosis must be based on the following:
- a sinus radiograph or CT scan performed within 48 hours pre-treatment
- with evidence of maxillary opacification or air/fluid levels
- Purulent discharge from the nose
- At least one of the following clinical signs and symptoms of acute bacterial sinusitis
- Lasting for more than 7 days prior to and no longer than 21 days before Evaluation 1: facial pain over the sinus or facial pressure over the sinus or facial tightness over the sinus or facial swelling or toothache.
- Subject must be a suitable candidate for oral antimicrobial therapy and is able to swallow capsules intact.
Exclusion
- Subjects who have: chronic sinusitis (signs and symptoms lasting greater than 28 days prior to Evaluation 1)
- Significant anatomical abnormalities of the sinuses
- Any other infection or condition which necessitates use of a concomitant systemic antimicrobial.
- History of any hypersensitivity or allergic reactions to penicillins, cephalosporins (including cefdinir), or quinolones (including levofloxacin).
- Subject who has taken: a systemic antibiotic within 14 days before study drug administration; a long acting injectable antibiotic (e.g., penicillin G benzathine) within 30 days before study drug administration.
- Known significant renal or hepatic impairment.
- Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological or endocrine disease, malignancy, or other abnormality (other than the disease being studied).
- Investigator considers the subject unsuitable for cefdinir or levofloxacin therapy, for any reason.
- Previous enrollment in this study.
- Any underlying condition or disease state that would interfere with the completion of the study procedures and evaluations or absorption of study drug.
- Subject who is currently receiving or who is likely to require any of the following medications during the period between Evaluation 1 (initial presentation to office/clinic) and Evaluation 3 (or within 48 hours after the last dose of study drug): Concomitant theophylline or any theophylline analog, unless plasma levels of these drugs can be adequately monitored during the study; Warfarin and probenecid.
- Immunocompromised subjects.
- Subject who requires parenteral antibiotic therapy for this infection or who has any other infection or condition, that necessitates use of a concomitant systemic antibiotic.
- Subjects receiving antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc within 2 hours before or after dosing with study drug.
- Subjects with a known or suspected central nervous system disorder that may predispose the subject to seizures or lower the seizure threshold.
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
271 Patients enrolled
Trial Details
Trial ID
NCT00645073
Start Date
November 1 2003
Last Update
March 27 2008
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35211
2
Birmingham, Alabama, United States, 35215
3
Columbiana, Alabama, United States, 35051
4
Eclectic, Alabama, United States, 36024